Introduction
============

*Staphylococcus aureus* is a human pathogen that causes nosocomial and community-associated infections that result in high rates of morbidity and mortality (Klevens et al., [@B27]; Deleo et al., [@B17]). The organism largely owes its ability to cause infection to the production of an array of virulence factors which, in the laboratory setting, are coordinately regulated in a cell density-dependent manner. Cell surface-associated factors are predominantly expressed during exponential phase growth whereas extracellular factors are predominantly produced during stationary phase growth (Novick, [@B31]; Bronner et al., [@B8]). The organism's virulence factors are also coordinately regulated in response to endogenous and exogenous cues, including cellular stresses and sub-inhibitory concentrations of antibiotics. A plethora of two component regulatory systems (TCRS) and nucleic acid-binding proteins have been hypothesized to modulate *S. aureus* virulence factor expression.

Of the 17 TCRS identified in *S. aureus* to date, the best-characterized is the accessory gene regulator (*agr*) locus. The *agr* locus encodes a quorum-sensing TCRS, AgrAC, whose regulatory effects are generally thought to be mediated by a regulatory RNA molecule, RNAIII. Within laboratory culture conditions, RNAIII expression peaks during the transition to stationary phase growth (Novick, [@B31]). RNAIII has been shown to modulate virulence factor expression by directly binding to target mRNA species, thereby affecting their stability and translation properties (Morfeldt et al., [@B30]; Huntzinger et al., [@B26]; Geisinger et al., [@B24]; Boisset et al., [@B6]). For instance, RNAIII binding to the cell surface factor protein A (*spa*) transcript creates a substrate for ribonuclease III digestion, which, in-turn, accelerates *spa* mRNA digestion and consequently limits Spa production (Huntzinger et al., [@B26]). Conversely, the binding of RNAIII to the extracellular virulence factor α-hemolysin (*hla*) transcript liberates the mRNA's Shine--Dalgarno sequence and increases Hla production (Morfeldt et al., [@B30]). Similar mechanisms of RNAIII regulation have been documented for the virulence factor *coa* (Chevalier et al., [@B13]) and the regulatory locus repressor of toxins (*rot*; Boisset et al., [@B6]).

In addition to TCRS, *S. aureus* produces a family of DNA-binding proteins that regulate virulence factor expression. The best-characterized to date is the staphylococcal accessory regulator nucleic acid-binding protein, SarA. The *sarA* locus consists of a 1.2 kb DNA region that produces three overlapping transcriptional units (*sarB*, *sarC*, and *sarA*), each of which terminates at the same site and encodes for the SarA protein (Chien and Cheung, [@B14]). Unlike RNAIII, SarA is constitutively produced throughout *S. aureus* growth phases, however the expression of the individual *sar* transcripts occurs in a growth phase-dependent manner; *sarA* and *sarB* are primarily transcribed during exponential phase growth whereas *sarC* is predominantly expressed during stationary phase growth (Manna et al., [@B28]; Blevins et al., [@B5]). SarA has been characterized as a pleiotropic transcriptional regulator of virulence factors that can bind to the promoter regions of a subset of genes that it regulates, such as *hla* (α-hemolysin) and *spa* (protein A; Chien and Cheung, [@B14]; Chien et al., [@B15]). Nonetheless, several observations have suggested that SarA's regulatory effects might be more complex than initially appreciated. Arvidson and colleagues have reported that, in addition to affecting *spa* transcript synthesis, SarA may also indirectly regulate Spa production (Tegmark et al., [@B38]). Further, no clear SarA consensus binding site has been defined; Cheung and colleagues found that SarA binds a 26 base pair (bp) region termed the SarA box, whereas Sterba et al. ([@B37]) have defined the SarA box to be a 7 bp sequence, which is present more than 1000 times within the *S. aureus* genome, indicating that the protein may have the capability of binding the chromosome more frequently than one might expect for a *bona fide* transcription factor (Chien et al., [@B15]). In that regard, others have suggested that SarA is a histone-like protein whose regulatory effects are a function of altering DNA topology and, consequently, promoter accessibility (Schumacher et al., [@B35]).

In *Escherichia coli*, histone-like proteins can post-transcriptionally regulate gene expression by binding directly to mRNA molecules and influencing the transcript's stability and translation (Balandina et al., [@B3]; Brescia et al., [@B7]). Accordingly, based on the possibility that SarA may behave as a histone-like protein, we hypothesized that the protein's regulatory effects may, in part, be due to its ability to bind and subsequently modulate the mRNA turnover properties of target transcripts. As a first step toward testing that prediction, we found that 138 mRNA species that are produced during *S. aureus* exponential phase growth, including the known SarA-regulated genes *spa* and *cna*, are also stabilized in a *sarA*-dependent manner (Roberts et al., [@B34]). More specifically, these mRNA transcripts are stabilized in a *sarA*^+^ background as compared to isogenic *sarA*^−^ cells, raising the possibility that SarA protein may bind these transcripts in a manner that affects their stability and, consequently, expression. In the current body of work we extended our evaluation of this phenomenon by investigating whether the mRNA turnover properties of late-exponential and/or stationary phase transcripts are also modulated in a *sarA*-dependent manner. Results revealed that this is indeed the case; the *sarA* locus affects the mRNA turnover properties of transcripts produced during both phases of growth. Further, using ribonucleoprotein immunoprecipitation (RIP-Chip) assays, we found that SarA binds these transcripts within *S. aureus* cells. Results were verified via gel-shift mobility assays. Taken together, these results indicate that SarA is capable of binding cellular mRNA species and that the protein's regulatory effects could be attributable to its ability to directly modulate the mRNA turnover properties of target mRNA species.

Materials and Methods
=====================

Growth conditions
-----------------

Bacterial strains and plasmids used in this study are listed in Table [1](#T1){ref-type="table"}. Overnight *S. aureus* cultures were diluted 1:100 into fresh brain--heart infusion (BHI) broth with a flask to volume ratio of 5:1 and were incubated at 37^o^C with aeration on a rotary shaker at 225 rpm. When cultures reached mid-exponential (OD~600\ nm~ = 0.25--0.30), late-exponential (OD~600\ nm~ = 1.1--1.2), or stationary (24 h post-inoculation) phase, rifampicin (200 μg ml^−1^; Sigma; St. Louis, MO) was added to arrest transcription. Aliquots of cells were removed at 0, 2.5, 5, 15, and 30 min post-transcriptional arrest, mixed with an equi-volume of ice-cold acetone:ethanol (1:1) and RNA was isolated, as previously described (Anderson et al., [@B1]; Roberts et al., [@B34]; Olson et al., [@B32]).

###### 

**Bacterial strains and plasmids used in this study**.

  Strains        Relevant genotype or phenotype                Reference
  -------------- --------------------------------------------- --------------------------------------------------
  UAMS-1         Wild type *S. aureus* osteomyelitis isolate   Gillaspy et al. ([@B25]); Cassat et al. ([@B11])
  UAMS-929       UAMS-1 (Δ*sarA*)                              Blevins et al. ([@B5])
  KLA43          UAMS-929 (pKLA40)                             This study
  RN4220         Restriction-deficient *S. aureus*             de Azavedo et al. ([@B16])
  INVαF          *E. coli* competent cells; *lacZ*ΔM15         Invitrogen
  DH5α           *E. coli* competent cells                     Invitrogen
  **Plasmids**   **Relevant genotype**                         
  pCRII          TOPO-TA cloning vector                        Invitrogen
  pBK123         Cam^R^ derivative of pCN51                    Charpentier et al. ([@B12])
  pKLA40         pBK123::c-Myc-SarA                            This study

Genechip^®^microarrays
----------------------

All microarray studies were performed as previously described (Anderson et al., [@B1], [@B2]; Roberts et al., [@B34]; Olson et al., [@B32]). Briefly, 10 μg of each bacterial RNA sample was labeled and hybridized to a *S. aureus* GeneChip®, following the manufacturer's recommendations for antisense prokaryotic arrays (Affymetrix; Santa Clara, CA). Average GeneChip® signal intensities for biological replicates (*n* ≥ 2) for each strain and time point were obtained from values normalized to exogenous transcripts. The half-life of each RNA transcript was determined using a "twofold" algorithm (Selinger et al., [@B36]) and was measured as the time point at which a given RNA signal intensity decreased two-fold as compared to that transcript at 0 min post-transcriptional arrest using GeneSpring 7.2 software (Agilent Technologies; Redwood City, CA).

*In vitro* transcription
------------------------

DNA templates consisting of the full-length *spa* transcriptional unit or derivatives containing 3′ or 5′ deletions were created by PCR amplification using UAMS-1 chromosomal DNA as a template and oligonucleotides listed in Table [2](#T2){ref-type="table"}. Resulting PCR products contained a 5′ T7 RNA polymerase promoter and transcription start site and were used as templates for generating corresponding RNA species using a T7 MegaScript *In vitro* Transcription Kit (Ambion; Austin, TX) according to the manufacturer's recommendations. Briefly, for transcription reactions, approximately 1 μg of PCR product was incubated for 3 h at 37^o^C with 7.5 mM of a NTP mix and T7 RNA polymerase to generate the indicated RNA species. Template DNA was degraded with four units of TurboDNase I for 15 min at 37^o^C, and *in vitro* transcribed RNA was recovered by lithium chloride precipitation and resuspended in nuclease-free water. RNA concentration of the synthesized product was determined spectrophotometrically (OD~260 nm~ 1.0 = 40 μg ml^−1^) and the integrity of the transcript was evaluated on a 1.2% agarose--0.66 M formaldehyde denaturing gel.

###### 

**Oligonucleotides used in this study**.

  Primer name                                                                    Sequence (5′ → 3′)
  ------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------
  **RT-PCR**                                                                     
  *cna* F                                                                        AACGAACAAGTATACACCAGGAGAG
  *cna* R                                                                        TTTGCTTTTTCATCTAATCCTGTC
  *norA* F                                                                       GCAGGTGCATTAGGCATTTTAGC
  *norA* R                                                                       TGCCGATAAACCGAACGCTAAG
  *spa* F                                                                        GCAGAAGCTAAAAAGCTAAATGATG
  *spa R*                                                                        GCTCACTGAAGGATCGTCTTTAAGG
  *sarA* F                                                                       TTTTAACCATGGCAATTACAAAAAT
  *sarA* R                                                                       TTTCTCTTTGTTTTCGCTGATGTAT
  **PCR-MEDIATED *IN VITRO* TRANSCRIPTION\***                                    
  L 1--450 *spa* T7 F                                                            **TAATACGACTCACTATAGGG**CATACAGGGGGTATTAATTTGAAAA
  L 1--450 *spa* R                                                               ATCCTAGAATTCTCTTCGTTCAAGTTAGGCATGTTCA
  L −250 *spa* T7 F                                                              **TAATACGACTCACTATAGGG**GTTCAACAAAGATCAACAAAGCGCC
  L −250 *spa* R                                                                 AGTAGAAAGTGTTGAGGCGTTTCAG
  **CLONING^[†](#tfn1){ref-type="table-fn"},[‡](#tfn2){ref-type="table-fn"}^**   
  c-Myc-SarA F                                                                   ATCCTA[GTCGAC]{.ul}GCTAACCCAGAAATACAATCACTGTGTC
  c-Myc-SarA R                                                                   AT[CCTAG]{.ul}*[G]{.ul}ATCCTTACAGATCTTCTTCGCTGATCAGTTTCTGTTC*TA GTTCAATTTCGTTGTTTGCTTCAGTG

*\*Bolded nucleotides indicate T7 promoter sequence*.

*^†^Underlined nucleotides indicate restriction sites*.

*^‡^Italicized nucleotides indicate the c-Myc epitope*.

Electrophoretic mobility shift assay
------------------------------------

*In vitro* transcribed *spa* mRNA or a PCR product containing the endogenous *hla* promoter were 3′ end-labeled with digoxigenin-ddUTP (DIG; Roche Applied Science; Indianapolis IN) following the manufacturer's recommendations. One picomole DIG-mRNA or -DNA was mixed with 0, 7.3, 36.6, 73.3, or 366.5 pmol purified SarA protein then, incubated for 15 min at 37^o^C in gel-shift buffer (20 mM HEPES-KOH, pH 8.0, 8 mM MgCl~2~, 100 mM NaCl), cooled on ice and the entire sample volume was electrophoresed in 1.2% agarose--0.66 M formaldehyde denaturing gels. Next, RNA-protein or DNA-protein complexes were transferred via capillary action to nylon membranes overnight in 20× SSC buffer (3 M NaCl, 300 mM sodium citrate, pH 7.0). Nucleic acid was then cross-linked to the membrane by UV irradiation in a Stratalinker® UV crosslinker (Stratagene; La Jolla, CA) twice at 1200 (×100) microjoules. Membranes were probed for presence of the DIG-labeled RNA or DNA using anti-DIG Fab fragments conjugated to alkaline phosphatase (1:10,000; Roche Applied Science) and visualized chemiluminescently with CSPD reagent (Roche Applied Science). For all binding assays, bovine serum albumin (BSA) was used as a negative control for non-specific RNA-protein and DNA-protein interactions.

c-Myc-SarA construction
-----------------------

A c-Myc epitope was translationally fused to the C-terminus of the SarA open reading frame. To do so, 615 bp of the *S. aureus* strain UAMS-1 *sarA* gene and its corresponding P1 promoter region were amplified by PCR using primers c-Myc-SarA F and c-Myc-SarA R (Table [2](#T2){ref-type="table"}); the latter included a c-Myc epitope and 3′ flanking restriction enzyme site. The resultant PCR product was gel-purified and digested with restriction enzymes *Sal*I and *Bam*HI and subcloned into pBK123 (Charpentier et al., [@B12]) to generate the plasmid pKLA40. Plasmid pKLA40 was then electroporated into the restriction-negative strain of *S. aureus*, RN4220 (de Azavedo et al., [@B16]) and transfected into UAMS-929 (*ΔsarA*) via Φ11-mediated phage to generate strain KLA43 and the plasmid was sequenced to confirm the integrity of the insert. c-Myc-SarA functionality was confirmed by examining the ability of the epitope-tagged protein to complement the exoprotein profile of UAMS-929(Δ*sarA*) cells. Briefly, supernates from stationary phase cultures of *S. aureus* UAMS-1, UAMS-929(Δ*sarA*), and KLA43 (Δ*sarA*; c-Myc-SarA) were collected, filtered through a 0.22 μm nylon membrane, and compared by electrophoresis in sodium dodecyl sulfate-polyacrylamide gels and silver staining (Bio-Rad Life Science, Hercules, CA).

Western blotting
----------------

Cultures were grown to the indicated growth phase and cells were mechanically disrupted in TE buffer in BIO101 lysing matrix B tubes using a FastPrep120 shaker (MP Biomedicals; Solon OH). Cell debris was removed by centrifugation at 4^o^C for 15 min and the protein concentration of supernatants were quantified by Bradford protein assays. For confirmation of c-Myc-SarA expression, 1 μg of protein was electrophoresed in a 15% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 10% milk in Tween-TBS (TTBS; TBS containing 0.1% Tween 20) and rabbit polyclonal anti-c-Myc antibody (1:1000; Sigma Aldrich; St. Louis, MO) was used to probe for presence of the c-Myc-SarA protein. Following incubation with the primary antibody, membranes were washed in TTBS and probed with peroxidase-conjugated anti-rabbit secondary antibody (1:1000; Promega; Madison, WI). Membranes were washed and c-Myc-SarA was detected chemiluminescently by ECL^TM^ (Amersham BioSciences; Piscataway NJ). Confirmation of successful RIP was confirmed by loading 10 μl of cell lysate, cell supernate, wash, or elution fractions and subjected to SDS-PAGE and western blotting, as described above.

Ribonucleoprotein immunoprecipitation (RIP-Chip)
------------------------------------------------

Ribonucleoprotein immunoprecipitation was performed using a c-Myc Tag/Co-IP Kit (Pierce Biotechnology; Rockford, IL). To do so, *S. aureus* strains UAMS-929 (*ΔsarA*; negative control) and KLA43 (*ΔsarA*/pKLA40::c-Myc-SarA) were grown to mid-exponential phase and RNA-binding proteins were cross-linked to RNA by incubating the cells for 30 min with 1% formaldehyde at room temperature. Cross-linking was quenched by adding 125 mM glycine for 5 min at room temperature. Cells were centrifuged at 3000 RPM for 10 min at 4^o^C and cell pellets were washed twice in 1 ml ice-cold TBS, resuspended in 350 μl of lysis buffer (10 mM Tris pH 8.0, 10 mM EDTA, 50 mM NaCl, and 1 mM PMSF) and were lysed by the addition 100 μg ml^−1^ lysostaphin (Ambi; Lawrence, NY) at 37^o^C for 30 min. Next, an equal volume of 2× immunoprecipitation (IP) buffer (100 mM Tris pH 8.0, 10 mM EDTA, 300 mM NaCl, 2% Triton X-100, 1 mM PMSF) was added and suspensions were incubated for an additional 10 min at 37^o^C. Nucleic acids were fragmented with a Sonic Dismembrator (Fisher) on ice twice for 15 s using an output setting of one with 15 s rests on ice between each pulse and cell debris was subsequently removed by centrifugation for 10 min at 4^o^C. Next, 800 μl of the supernatant was mixed with 10 μl of anti-c-Myc agarose (Pierce Biotechnology; Rockford IL) and then added to IP spin columns (Pierce Biotechnology) and incubated overnight at 4^o^C to collect c-Myc-SarA/RNA and DNA complexes. Columns were washed five times with 1× IP buffer and c-Myc-SarA complexes were eluted in 50 μl of elution buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) by first incubating at 65^o^C for 10 in followed by centrifugation at 4^o^C to collect eluate. Cross-linking was reversed by incubating eluate for 2 h at 42^o^C and then 6 h at 65^o^C in 0.5× elution buffer containing 0.8 mg ml^−1^ pronase. For chromatin immunoprecipitation (ChIP-chip) experiments used to detect known SarA-DNA interactions, liberated DNA was purified using a PCR Clean-Up Kit (Qiagen) per manufacturer's recommendations and hybridized to a GeneChip® and processed as described above. For RIP-chIP experiments, liberated nucleic acid was treated with 17 U of RNase-Free DNase I (Qiagen) and RNA was purified using a Clean and Concentrator Kit (Zymo Research; Orange, CA) according to the manufacturer's recommendations. All assays were performed in triplicate for each strain and purification of the c-Myc-SarA protein was confirmed via Western blotting. Following IP, bacterial RNA was amplified and reverse-transcribed using a MessageAmp II-Bacteria Prokaryotic RNA Amplification Kit (Ambion). 1.5 μg of the amplified cDNA was then hybridized to a GeneChip® and processed as described above. The fold change in average signal intensity of KLA43 replicates as compared to the average signal intensity of UAMS-929 (negative control) replicates was calculated for each GeneChip® qualifier. SarA was considered to bind DNA or transcripts that exhibited a signal intensity that was ≥ two-fold in KLA43 samples and greater than two standard deviations from the average signal intensity (background), as compared to UAMS-929 cells.

Quantitative reverse-transcription PCR
--------------------------------------

For standard qRT-PCR reactions, 25 ng of total bacterial RNA were reverse-transcribed, amplified, and measured using a LightCycler® RNA Master SYBR Green I kit per the manufacturer's recommendations (Roche Applied Science). As an internal control by which to standardize RNA loading, 0.5 pg of RNA was used to quantitate the amount of 16S rRNA in each sample. Transcript concentrations were calculated using LightCycler® software and LightCycler® Control Cytokine RNA titration kit as a standard for determining the copies of each transcript present per reaction. Final concentration values are listed as normalized to 16S rRNA abundance. Transcript half-lives were calculated as the time point at which RNA titers exhibited a ≥ two-fold decrease in signal intensity.

Results
=======

It is well recognized that SarA is a pleiotropic regulator of *S. aureus* virulence factors, yet the mechanism(s) by which the protein affects gene expression is incompletely understood. Several studies have shown that the molecule affects the transcript synthesis of target genes, however the lack of a consensus SarA-binding sequence and evidence of indirect control of gene expression have implicated SarA in post-transcriptional control of gene expression. Accordingly, it has also been hypothesized that SarA regulates *S. aureus* gene expression via modulating the mRNA turnover properties of target transcripts. In support of this hypothesis, we have previously shown that 138 mRNA species, including the virulence factor transcripts protein A (*spa*) and collagen-binding protein (*cna*) are stabilized in a *sarA*-dependent manner (Roberts et al., [@B34]). Our current efforts are designed to expand upon these initial studies and further define the role for *sarA* in modulating mRNA turnover.

*sarA* stabilizes subsets of mRNA species in a growth phase-dependent manner
----------------------------------------------------------------------------

Herein, we set out to establish whether the degradation properties of mRNA species that are expressed during late-exponential and/or stationary phase growth are affected by a product of the *sarA* locus. To do so, *S. aureus* UAMS-1 (wild type) and UAMS-929 (UAMS-1Δ*sarA*) were grown to late-exponential or stationary phase growth and transcription was halted by the addition of rifampicin. Total bacterial RNA was then purified from aliquots of cells at 0, 2.5, 5, 15, and 30 min post-transcriptional arrest and the mRNA titers of expressed transcripts were then measured using Affymetrix GeneChips®. A comparsion of each transcript's titer at 0 min post-transcriptional arrest to that of each subsequent time point allowed the half-lives of each mRNA to be measured, as previously described (Anderson et al., [@B1], [@B2]; Roberts et al., [@B34]; Olson et al., [@B32]).

As shown in Figure [1](#F1){ref-type="fig"}, in general terms, the global RNA turnover properties of UAMS-1 and UAMS-1Δ*sarA* cells exhibited a similar trend that is consistent with our previous observations; bulk mRNA turnover occurs more rapidly in exponential phase as compared to stationary phase cells (Olson et al., [@B32]). Despite these similarities, a more detailed analysis of RNA degradation properties of individual mRNA species within each strain background indicated that *sarA* influences the stability of many transcripts. More specifically, 93.2 and 48.4% of transcripts exhibited half-lives of \<2.5 min during late-exponential and stationary phase growth, respectively, in the wild type strain (Table [3](#T3){ref-type="table"}). Conversely, 76.9 and 32.5% of transcripts were degraded within 2.5 min in late-exponential and stationary phase Δ*sarA* cells, suggesting that *sarA* affects the stability of a subset of transcripts. Within this subset, 68 (3.2%; Supplemental Table S1 in Supplementary Material) and 325 (15.3%; Supplemental Table S2 in Supplementary Material) of late-log and stationary phase transcripts, respectively, were less stable in *ΔsarA* cells, indicating that they are stabilized in a *sarA*-dependent manner. Conversely, 385 (18.2%; Supplemental Table S3 in Supplementary Material) and 580 (27.2%; Supplemental Table S4 in Supplementary Material) of transcripts were more stable in *ΔsarA* cells, indicating that, like RNAIII, SarA may facilitate degradation of a particular subset of mRNA species.

![**Global transcript turnover properties of wild type and Δ*sarA* cells**. The global RNA turnover properties of UAMS-1 (wild type) and isogenic *ΔsarA* (*ΔsarA*) cells during late-exponential (LE) and stationary phase (SP) growth are graphed. Percentages of total transcripts with half-lives of ≤2.5, 2.5--5, 5--15, 15--30, and ≥30 min are shown.](fcimb-02-00026-g001){#F1}

###### 

***S. aureus* growth phase mRNA degradation**.

               UAMS-1                                  *ΔsarA*                                                                                                                                         
  ------------ --------------------------------------- --------- --------------------------------------- ------ --------------------------------------- ------ --------------------------------------- ------
  ≤2.5 min     2044                                    93.2      1115                                    48.4   1620                                    76.9   691                                     32.5
  2.5--5 min   36                                      1.6       648                                     28.1   359                                     17.0   1032                                    48.5
  5--15 min    92                                      4.2       389                                     16.9   104                                     4.9    294                                     13.8
  15--30 min   16                                      0.7       103                                     4.5    9                                       0.4    69                                      3.2
  \>30 min     4                                       0.2       47                                      2.0    15                                      0.7    40                                      1.9
  Total        2192[^a^](#tfn3){ref-type="table-fn"}   100       2302[^b^](#tfn4){ref-type="table-fn"}   100    2107[^c^](#tfn5){ref-type="table-fn"}   100    2126[^d^](#tfn6){ref-type="table-fn"}   100

*^a^55 RNA species could not be measured*.

*^b^27 RNA species could not be measured*.

*^c^38 RNA species could not be measured*.

*^d^18 RNA species could not be measured*.

*sarA* affects virulence factor mRNA stability
----------------------------------------------

Results also indicated that the mRNA turnover properties of many virulence factors are influenced by *sarA*, but that these effects predominantly occur during stationary phase growth. More specifically, during late-exponential phase growth the transcripts coding for three virulence-associated genes were stabilized in a *sarA*-dependent manner (Table [4](#T4){ref-type="table"}). Among these were two metabolic enzymes, enolase (*eno*; Carneiro et al., [@B9]) and carbamate kinase (*arc*; Beenken et al., [@B4]; Diep et al., [@B18]; Diep and Otto, [@B19]), both of which exhibited half-lives of 30 min in wild type cells but only 15 min in *ΔsarA* cells. Likewise, the ATP-dependent protease *clpP* (Frees et al., [@B22], [@B23];Michel et al., [@B29]), exhibited a half-life of 15 min in wild type cells, but was reduced to five min in the *sarA*-mutant. During stationary phase growth at least 13 virulence factor transcripts were stabilized in a *sarA*-dependent manner (Table [4](#T4){ref-type="table"}). Included among these were: *spa* (protein A), *hla* (α-hemolysin), *hlb* (β-hemolysin), and *hlgCB* (γ-hemolysin), as well as members of the capsule operon (*cap*) and the cell surface-associated factors *fnbA* (encoding fibronectin binding protein A) and *cna* (encoding a collagen-binding protein). Quantitative RT-PCR-based determination of select virulence factor half-lives within stationary phase wild type and Δ*sarA* cells verified the microarray-based RNA turnover measures (Table [5](#T5){ref-type="table"}). In addition to virulence factors, three virulence factor regulatory molecules, *agrA*, *sarS*, and *saeS*, were stabilized in a *sarA*-dependent manner.

###### 

***sarA-*stabilized virulence-associated transcripts**.

  Common name**^[†](#tfn8){ref-type="table-fn"}[‡](#tfn9){ref-type="table-fn"}^**   Half-life\*                              Description                              
  --------------------------------------------------------------------------------- ---------------------------------------- ---------------------------------------- --------------------------------------
  **LATE-EXPONENTIAL**                                                                                                                                                
  *arcC*                                                                            30 min                                   15 min                                   Carbamate kinase
  *clpP*                                                                            15 min                                   5 min                                    ATP-dependent protease
  *eno*                                                                             30 min[\*](#tfn7){ref-type="table-fn"}   15 min                                   Enolase
  *spa*^[‡](#tfn9){ref-type="table-fn"}^                                            Stable[\*](#tfn7){ref-type="table-fn"}   Stable[\*](#tfn7){ref-type="table-fn"}   Protein A
  **STATIONARY**                                                                                                                                                      
  *agrA*                                                                            Stable[\*](#tfn7){ref-type="table-fn"}   30 min                                   AgrAC TCRS response regulator
  *arcB*                                                                            15 min                                   5 min                                    Ornithine carbamoyltransferase
  *cap5A*                                                                           5 min                                    2.5 min                                  Capsular polysaccharide biosynthesis
  *cap5C*                                                                           15 min                                   5 min                                    Capsular polysaccharide biosynthesis
  *cap5D*                                                                           15 min                                   5 min                                    Capsular polysaccharide biosynthesis
  *cna*                                                                             15 min                                   5 min                                    Collagen-binding protein
  *fnbA*                                                                            15 min                                   5 min                                    Fibronectin binding protein A
  *hla*^[‡](#tfn9){ref-type="table-fn"}^                                            Stable                                   30 min                                   α-hemolysin
  *hlb*                                                                             30 min                                   15 min                                   Phospholipase C
  *hlgB*                                                                            30 min                                   15 min                                   γ hemolysin component B
  *hlgC*                                                                            15 min                                   5 min                                    γ hemolysin component C
  *norA*                                                                            15 min                                   5 min                                    Multi drug transporter
  *rsbV*                                                                            5 min                                    2.5 min                                  Anti--anti-sigma factor
  SACOL0390                                                                         Stable                                   30 min                                   Lipase
  *saeR*                                                                            15 min[\*](#tfn7){ref-type="table-fn"}   5 min                                    SaeRS TCRS response regulator
  *sarV*                                                                            5 min                                    2.5 min                                  SarA homolog
  *spa*^[‡](#tfn9){ref-type="table-fn"}^                                            30 min[\*](#tfn7){ref-type="table-fn"}   15 min[\*](#tfn7){ref-type="table-fn"}   Protein A

*\*Estimated half-life due to detection limits of the system*.

*^†^*S. aureus* strain N315 loci unless otherwise noted*.

*^‡^Transcript synthesis affected by *sarA* in UAMS-1 cells (Cassat et al., [@B10])*.

###### 

**Stationary phase mRNA half-lives of selected virulence factor transcripts as calculated by qRT-PCR[\*](#tfn10){ref-type="table-fn"}**.

               Wild type[^†^](#tfn11){ref-type="table-fn"}   *ΔsarA*[^†^](#tfn11){ref-type="table-fn"}
  ------------ --------------------------------------------- -------------------------------------------
  ***spa***                                                  
  0 min        1.00                                          1.00
  5 min        1.06                                          1.34
  15 min       1.22                                          1.63
  30 min       2.43                                          5.56
  60 min       2.47                                          11.28
  ***norA***                                                 
  0 min        1.00                                          1.00
  5 min        1.45                                          3.14
  15 min       2.20                                          3.22
  30 min       3.14                                          6.99
  60 min       3.20                                          5.38
  ***cna***                                                  
  0 min        1.00                                          1.00
  5 min        1.02                                          2.49
  15 min       2.68                                          2.07
  30 min       18.66                                         6.22
  60 min       83.91                                         35.33

*\*Time point corresponding to ≥ two-fold decrease (half-life) is shaded gray*.

*^†^Values represented as fold-change normalized to mRNA titers at 0 min*.

SarA binds mRNA *in vitro*
--------------------------

The results presented here are consistent with previous observations suggesting that the *sarA* locus affects *S. aureus* mRNA turnover properties with exponential phase cells (Roberts et al., [@B34]). The two most likely scenarios that could account for these observations are that a product of the *sarA* locus may directly interact with and subsequently affect the mRNA degradation properties of target transcripts or that SarA indirectly modulates the organism's mRNA turnover properties by regulating other factors that affect *S. aureus* RNA decay. As a preliminary means of distinguishing between these two possibilities we set out to determine whether SarA is an RNA-binding protein. To do so, electrophoretic mobility shift assays (EMSAs) were performed to investigate whether purified SarA protein directly binds to *spa* transcripts, an mRNA species that is stabilized in a *sarA*-dependent manner (Roberts et al., [@B34]). Accordingly, various amounts (0, 7.3, 36.6, 73.3, or 366.5 pmol) of purified SarA protein were incubated with DIG-labeled, *in vitro* transcribed *spa* mRNA, during experimental conditions that have previously been used to establish that SarA binds to the promoter region of the α-hemolysin (*hla*) gene (Chien et al., [@B15]). As shown in Figure [2](#F2){ref-type="fig"}A, during these assay conditions SarA protein did indeed bind to the *hla* promoter region, confirming that the experimental conditions are appropriate to measure SarA-nucleic acid interactions and further validating the work of Chien et al. ([@B15]). Similarly, the EMSA revealed that SarA elicited a dose-dependent shift in mobility of labeled *spa* mRNA, suggesting that SarA may be capable of binding RNA molecules (Figure [2](#F2){ref-type="fig"}B). Gel-shift assays were also performed with BSA and a *S. aureus* stable RNA, SSR42 (Olson et al., [@B32]), to determine if non-staphylococcal proteins would bind to the *in vitro* transcribed mRNA and whether SarA alters the mobility of any RNA species, respectively. Results of those studies indicated that BSA did not affect the mobility of *spa* transcript and, likewise, that SarA did not affect the migration of *in vitro* transcribed SSR42 (Figure [2](#F2){ref-type="fig"}C).

![**SarA binds mRNA *in vitro***. **(A)** Gel mobility shift assays evaluating the mobility of DIG-labeled *hla* promoter DNA (P*~hla~*) in the presence of increasing amounts of purified SarA protein (0, 7.3, 36.6, 73.3, or 366.5 pmol). **(B)** Gel mobility shift assays evaluating the mobility of DIG-labeled, *in vitro* transcribed *spa* in the presence of increasing concentrations of SarA protein (0, 7.3, 36.6, 73.3, or 366.5 pmol). **(C)** Gel mobility shift assays evaluating the mobility of DIG-labeled, *in vitro* transcribed *SSR42* in the presence of increasing concentrations of SarA protein (0, 36.6, 73.3, or 366.5 pmol). **(D)** Schematic of transcript variants containing deletions of 3′ or 5′ regions of *spa* that were DIG-labeled for use in subsequent gel-shift assays. (**E)** Gel mobility shift assays evaluating the mobility DIG-labeled *spa* deletion variants in the presence of 73.3 pmol SarA.](fcimb-02-00026-g002){#F2}

RNA-binding proteins have been shown to bind to specific regions of target mRNAs (Folichon et al., [@B21]; Wang et al., [@B39]); to test this possibility with SarA, we used EMSAs to measure the protein's ability to bind different regions of *in vitro* transcribed *spa* mRNA: a region lacking bases 1--320 of the 5′ end (L-250) and a fragment of *spa* containing only bases 1--450 (L 1--450; Figure [2](#F2){ref-type="fig"}D). As seen in Figure [2](#F2){ref-type="fig"}E, SarA affected the mobility of both RNA species. Further, a higher molecular weight product was observed when SarA was incubated with *spa* RNA fragments containing an intact 5′region (450 nt) in comparison to fragments lacking bases 1--250 of the transcript (1,100 nt), suggesting that the 5′ end of the *spa* transcript may harbor a greater number of SarA-binding sites than the 3′ terminus. Taken together, these results suggest that SarA may be capable of binding both DNA and RNA molecules.

SarA binds mRNA *in vivo*
-------------------------

Based on the observations that many exponential phase transcripts, including *spa*, are stabilized in a *sarA*-dependent manner and that SarA protein is capable of altering the mobility of *spa* transcripts *in vitro*, we set out to determine whether the protein is capable of binding mRNA species within bacterial cells using ribonucleoprotein immunoprecipitation-microarray (RIP-Chip) assays. To do so, we needed to create a means of capturing cellular SarA protein. Accordingly, the SarA open reading frame was translationally fused to a C-terminal c-Myc epitope. This construct was placed under control of the *sarA* endogenous P1 promoter and was inserted into plasmid pCN51 to generate pKLA40. This plasmid was transfected into UAMS-929 (*ΔsarA*) cells to generate strain KLA43 and the expression properties of C-Myc-SarA protein were evaluated. It should be noted that the c-Myc epitope has been shown to exhibit little or no non-specific nucleic acid binding in previous assays (Pannone et al., [@B33]). As expected, RT-PCR and Western blotting using anti-c-Myc antibodies established that the chimeric protein was expressed within KLA43 cells (Figures [3](#F3){ref-type="fig"}A,B) during mid- and late-exponential as well as stationary phase growth. We also confirmed that c-Myc-SarA was capable of complementing SarA's regulatory effects within *ΔsarA* cells. Specifically, *sarA*-mutant cells have been reported as exhibiting altered exprotein profiles due to alterations in the control of gene expression (Tegmark et al., [@B38]). Thus, we evaluated the ability of the c-Myc-SarA construct to complement the exoprotein profile of supernates from stationary phase cultures of *S. aureus* strain UAMS-929 (Δ*sarA*). As shown in Figure [3](#F3){ref-type="fig"}C, the c-Myc-SarA construct at least partially complemented the exoprotein profile of Δ*sarA* cells, indicating that presence of the epitope did not significantly affect SarA's regulatory capacity and, consequently, the chimeric protein was appropriate for studying SarA's cellular role as an RNA-binding protein.

![**SarA binds mRNA *in vivo***. (**A)** RT-PCR based detection of c-Myc-SarA transcript expression in Δ*sarA* and Δ*sarA* harboring plasmid pKLA40 harboring a c-Myc-SarA construct under control of the *sarA* P1 promoter during mid-exponential (ME), late-exponential (LE), and stationary (SP) phase growth. (**B)** Western blotting based detection of c-Myc-SarA chimeric protein from *sarA* and Δ*sarA* harboring plasmid pKLA40; lysates collected during mid-exponential (ME), late-exponential (LE), and stationary (SP) phase growth. **(C)** SDS-PAGE and silver staining of exoproteins purified from wild type, Δ*sarA* and Δ*sarA* harboring plasmid pKLA40 stationary phase culture supernates. **(D)** RNA immunoprecipitation (RIP) was performed by capturing c-Myc-SarA protein cross-linked to nucleic acids. Successful immunoprecipitation was confirmed by Western blotting of cell lysate (L), lysate supernate (SN), wash (W), and elution (E) fractions with anti-c-Myc antibody.](fcimb-02-00026-g003){#F3}

Having confirmed that the chimeric protein was expressed and functional within Δ*sarA* cells, RIP-chIP assays were performed using anti-c-Myc immunoglobulin immobilized on agarose beads to capture cellular c-Myc-SarA-bound transcripts. To do so, KLA43 (Δ*sarA* c-Myc-SarA) was grown to mid-exponential phase and the proteins were cross-linked to nucleic acids with 1% formaldehyde to stabilize any interactions between c-Myc-SarA and RNA molecules. Cells were lysed and c-Myc-SarA protein was then immunoprecipitated with the anti-c-Myc agarose beads, co-precipitating any bound RNA species. Western blotting of the cell lysates and RIP intermediates indicated the presence of the epitope-labeled SarA through sequential steps of the IP process (Figure [3](#F3){ref-type="fig"}D). After reversal of the RNA cross-linking, the RNA was purified, treated with DNase, amplified, labeled, and applied to a *S. aureus* GeneChip®. All RIP-Chip assays were performed in triplicate for both KLA43 (Δ*sarA* c-Myc-SarA) and Δ*sarA* cells (negative control). A transcript was considered to be bound by c-Myc-SarA if its average signal intensity value was ≥ two-fold in KLA43 cells as compared to the negative control. It should be noted that as a prerequisite to performing RIP-Chip assays we exploited SarA's known ability to bind the *hla* promoter region and the fact that the microarray used in this study contains intergenic regions representing gene promoters to determine whether our experimental approach was appropriate for studying cellular SarA-nucleic acid interactions. Results from ChIP-chip experiments revealed that the signal intensity of the intergenic region representing the *hla* promoter region exhibited a signal increase beyond the established threshold (≥ two-fold) in samples from KLA43 cells as compared to UAMS-929 cells, indicating that the experimental approach was capable of detecting known *in vitro* protein-nucleic acid reactions *in vivo* (data not shown).

RIP-Chip assays results indicated that cellular c-Myc-SarA is capable of binding to a total of 115 RNA species, including eight virulence factor transcripts (Supplemental Table S5 in Supplementary Material). Of the virulence factor transcripts bound by SarA (Table [6](#T6){ref-type="table"}), *spa* and *arcB* were also stabilized in a *sarA*-dependent manner in at least one of the growth phases studied here (late-log and stationary phase) or by our laboratory previously (mid-exponential phase; Roberts et al., [@B34]). Thus, our collective results indicate that *spa* mRNA is stabilized in a *sarA*-dependent manner (Roberts et al., [@B34]) and that SarA protein is capable of binding the transcript during *in vitro* conditions and within bacterial cells. When taken together, these results suggest that SarA may post-transcriptionally regulate gene expression by binding to and modulating the RNA degradation properties of target transcripts.

###### 

**Virulence-associated transcripts bound by cellular c-Myc-SarA**.

  Common name[\*](#tfn12){ref-type="table-fn"}   Fold change^[†](#tfn13){ref-type="table-fn"}^   mRNA stability^[‡](#tfn14){ref-type="table-fn"}^   Description
  ---------------------------------------------- ----------------------------------------------- -------------------------------------------------- --------------------------------------------
  *arcB*                                         8.3                                             Stabilized                                         Ornithine carbamoyltransferase
  *pfoR*                                         3.7                                             Destabilized                                       Perfringolysin O regulator protein
  *rsbW*                                         7.6                                                                                                Anti-sigma B factor
  SA0097                                         8.3                                             Destabilized                                       Transcriptional regulator AraC/XylS family
  *sarZ*                                         2.7                                                                                                SarA homolog
  *sbi*                                          3.3                                             Destabilized                                       IgG-binding protein
  *spa*                                          4.2                                             Stabilized                                         IgG-binding protein A
  *srtA*                                         7.4                                                                                                Sortase

*\**S. aureus* strain N315 locus*.

*^†^Fold change of signal intensities present in c-Myc-SarA samples in comparison to Δ*sarA* samples (*p* \< 0.05)*.

*^‡^Effect of *sarA* on transcript turnover*.

Discussion
==========

Staphylococci produce an array of TCRS and DNA-binding proteins that are thought to modulate virulence factor transcript synthesis, providing the pathogen with a means for sensing and responding to environmental stresses including exposure to sub-inhibitory concentrations of antibiotics (Novick, [@B31]). By definition, transcript titers are a function of both transcript synthesis and degradation, and mounting evidence strongly suggests that orchestrated changes in mRNA degradation mediate the organism's ability to regulate gene expression. Indeed, the global mRNA degradation properties of *S. aureus* are significantly altered in response to growth phase, stringent response-inducing conditions, and pH and temperature stress (Anderson et al., [@B1], [@B2];Olson et al., [@B32]). With respect to growth phase, RNA turnover is rapid in exponential phase cells whereas a global stabilization of RNA transcripts occurs during stationary phase growth; ∼90% of transcripts decay within 5 min during mid-exponential growth while only ∼50% of all transcripts decay within 5 min during stationary phase growth (Olson et al., [@B32]). Presently, the factors that mediate this transition between RNA degradation profiles are poorly characterized. Because all transcripts do not degrade at the same rate, it has been hypothesized that *trans*-acting factors, such as RNA-binding proteins or regulatory RNAs, may affect mRNA stability. Indeed, the mRNA turnover properties of nearly 150 exponential phase mRNA species, including the cell surface-associated virulence factors *spa* and *cna*, have been reported to be stabilized in a *sarA*-dependent manner (Roberts et al., [@B34]). However, those studies were limited in scope, in that the effects of *sarA* on RNA stability were only studied within mid-exponential phase cells. In the present work, we evaluated the effects of *sarA* on late-exponential and stationary phase RNA turnover.

A comparison of mRNA turnover within wild type and *ΔsarA* cells indicated that global RNA decay is similar between the two strains; mRNA is rapidly degraded in late-exponential phase cells but transcripts become more stable during stationary phase growth. Despite these similarities, transcript turnover within each growth phase was slightly decreased in *ΔsarA* cells indicating that a product of the *sarA* locus affects the stability of a subset of mRNA species. Indeed, *sarA* was found to both stabilize and destabilize transcripts in each growth phase; 3.4 and 16.5% of transcripts were stabilized, whereas 16.4 and 23.5% of transcripts were destabilized in a *sarA*-dependent manner within late-exponential and stationary phase cells, respectively. Among the stabilized transcripts were those encoding for translation machinery, suggesting that *sarA* may modulate protein production indirectly by post-transcriptionally altering expression of the translation apparatus. Perhaps more relevant to *S. aureus* pathogenesis, 19 virulence-associated factors were stabilized in a *sarA*-dependent manner, including cell surface components, secreted enzymes and toxins, transcriptional regulators, and antibiotic resistance determinants. Interestingly, a subset of these virulence factors, including *spa*, *hla, sak*, and *sspB* have been previously shown to be regulated by *sarA* at the transcriptional level (Cassat et al., [@B10]). These results suggest that the effects of *sarA* on gene regulation in *S. aureus* may be more complex than previously thought, and that a product of the locus may post-transcriptionally regulate gene expression.

The *sarA* locus is capable of producing three distinct transcripts, each of which encode for and result in the production of SarA protein. Thus, any potential post-transcriptional regulation could occur via the SarA protein or via one of the transcribed mRNAs as has been described with other regulatory RNAs in *S. aureus* (reviewed in Felden et al., [@B20]). The mRNA turnover properties of *ΔsarA* cells harboring plasmid-borne copies each of these three transcriptional units demonstrated that their RNA degradation properties mimicked one-another, suggesting that the SarA protein (as opposed to a particular *sarA* transcriptional unit) accounts for the *sarA*-dependent modulation of mRNA turnover (data not shown). Thus, we predicted that SarA directly or indirectly affects the RNA degradation properties of target transcripts. Accordingly, gel-shift assays were performed to determine whether SarA protein directly binds to *spa* mRNA *in vitro*, a transcript that is stabilized in a *sarA*-dependent manner. EMSA results revealed that SarA alters the mobility of *spa* mRNA in a concentration-dependent manner, suggesting that the protein is capable of binding the transcript in a cooperative manner. We hypothesize that this may reflect two potential dynamic properties of the interaction: (1) SarA oligomerizes when binding RNA or (2) the *spa* transcript contains multiple SarA-binding sites such that in the presence of excess SarA the number of sites bound by the protein are increased. Further, gel-shift assays indicated that SarA exhibits a greater propensity to cause a higher molecular shift of the 5′-end of *spa* mRNA, suggesting that either the 5′ end of the message harbors a higher incidence of SarA-binding sites or that the secondary structure of the transcript's 5′ end reduces the amount of steric hindrance. Regardless, we conclude from the results of these assays suggest that the SarA-mRNA interaction is not likely to be equal across the entire length of the *spa* transcript.

In order to characterize the physiological relevance of SarA's potential RNA-binding properties, we performed *in vivo* RIP-chIP assays to identify the transcripts with which the protein could interact within bacterial cells. To do so, c-Myc epitope-tagged SarA was expressed in *ΔsarA* cells and immunoprecipitated; c-Myc-SarA-bound RNA molecules were subsequently identified using GeneChips®. In total, SarA was found to interact with 115 mRNA species, including eight virulence factors. Specifically, two of the virulence factor transcripts that bound to SarA *in vivo* were also found to be stabilized in a *sarA*-dependent manner, including the *spa* transcript, an mRNA species that SarA appears to bind *in vitro*. Taken together, these data suggest that SarA may alter the stability of target transcripts by directly binding to these mRNA species, which could, in-turn, limit the RNA molecule's accessibility to degradation machinery. Additionally, SarA also interacted with three transcripts that are destabilized in a *sarA*-dependent manner, suggesting that the protein:mRNA interaction may catalyze a conformational change in the substrate RNA molecule that makes it more susceptible to ribonuclease attack. In addition to ORFs, SarA also bound five transcripts that mapped to intergenic regions and may represent non-coding RNA molecules.

Collectively, the data presented here indicate that SarA interacts with RNA in a biologically relevant setting and that these interactions correlate with alterations in the degradation properties of a subset of those mRNA species. Thus, we hypothesize that SarA post-transcriptionally regulates gene expression via binding to and consequently modulating the mRNA turnover properties of target transcripts. There is precedence for this prediction in other organisms. For instance, in *Escherichia coli*, CsrA is an RNA-binding protein that modulates virulence factor expression, in part, by both stabilizing and destabilizing target transcripts. For instance, CsrA associates with the 5′ untranslated region of the *pgaA* transcript, which blocks translation of the molecule and subsequently destabilizes the transcript (Wang et al., [@B39]). CsrA has also been shown to bind the *flhDC* transcript, stabilizing the molecule and ultimately contributes to bacterial motility (Wei et al., [@B40]). Given the similarities of CsrA and other RNA-binding proteins to SarA, scenarios by which SarA can post-transcriptionally modulate gene expression emerge. In the case of *spa*, whose transcript is stabilized but protein production is repressed by SarA, binding of the RNA may simultaneously inhibit activity of the translational machinery and ribonucleases (RNases). This mechanism would presumably provide the cell with a mechanism to repress protein A production, in a manner that when inactivated would allow for efficient induction of Spa production without having to expend energy to synthesize new transcripts. Our finding that SarA seems to preferentially interact with the 5′ terminus of the *spa* transcripts supports this prediction, as the 5′end of mRNA not only serves as a potential entry point for the RNA degradation machinery, it is also the loading site for the translation apparatus. Similarly, the binding of SarA to transcripts which are normally stabilized and for which protein levels are increased, SarA could function by inhibiting degradation of the transcript by RNases, thus facilitating increased production of protein. As what occurs with CsrA, SarA also destabilizes transcripts that it binds *in vivo*, suggesting that this interaction could expose transcripts to cleavage by RNases. It was also observed that virulence factor transcripts that were stabilized in a *sarA*-dependent manner were not bound by SarA *in vivo* (Supplemental Table S5 in Supplementary Material). Thus, one can assume that the modulation of RNA stability of these transcripts is indirect; presumably, SarA regulates another factor, such as a regulatory RNA or other RNA-binding protein, which ultimately mediates the alteration in stability. While the biological significance of *sarA*-dependent control of mRNA stability is not yet fully understood, these results indicate that SarA is an RNA-binding protein with the potential to post-transcriptionally regulate the mRNA and consequently protein production of target transcripts. These results may have expanded significance in that SarA represents a prototypical regulatory molecule with a multitude of homologs within *S. aureus* and other bacterial pathogens.
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**Late-exponential phase transcripts stabilized in a *sarA*-dependent manner**.
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Click here for additional data file.
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**Stationary phase transcripts stabilized in a *sarA*-dependent manner**.
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**Late-exponential phase transcripts destabilized in a *sarA*-dependent manner**.
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**Stationary phase transcripts destabilized in a *sarA*-dependent manner**.
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**Mid-exponential growth phase transcripts bound by SarA *in vivo***.
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Click here for additional data file.
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